Between Dec 19, 2024 and Jan 2, 2025, datasets can be submitted to DRUM but will not be processed until after the break. Staff will not be available to answer email during this period, and will not be able to provide DOIs until after Jan 2. If you are in need of a DOI during this period, consider Dryad or OpenICPSR. Submission responses to the UDC may also be delayed during this time.

Browsing by Subject "Metabolic dysregulation"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    IGF-1 stimulates glycolytic ATP production in MCF-7L cells
    (2023-07) Rajoria, Bhumika
    The Insulin-like Growth Factor (IGF) system in breast cancer progression has been a matter of interest for decades, but targeting this system did not result in a successful clinical strategy. The system’s complexity, and homology of its two receptors - insulin receptor (IR) and type 1 insulin-like growth factor receptor (IGF-1R) are possible causes. The IGF system maintains cell proliferation and regulates metabolism, making it a pathway to explore. To understand the metabolic phenotype of breast cancer cells, we quantified their real-time ATP production rate upon acute stimulation with ligands – insulin-like growth factor 1 (1GF-1) and insulin. MCF-7L cells express both IGF-1R and IR, while tamoxifen-resistant MCF-7L (MCF-7L TamR) cells have downregulated IGF-1R with unchanged IR levels. Treating MCF-7L cells with 5nM IGF-1 increased the glycolytic ATP production rate while 10nM insulin did not affect metabolism when compared with control. Neither treatment altered ATP production in MCF-7L TamR cells. The study provides evidence of the relationship between metabolic dysfunction, cancer, and the IGF axis. In these cells, IGF-1R, and not IR, regulates ATP production.